XELOX stop-and-go trial:A phase 2 study of 1st line chemotherapy for unresectable or recurrent colorectal cancer.
收藏NIAID Data Ecosystem2026-03-06 收录
官方服务：
资源简介：
Interventions: XELOX therapy 6 courses, followed by XELODA 6 courses, then XELOX Primary outcome(s): Progression free survival Study Design: Single arm Non-randomized
创建时间：
2010-05-15
